We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral etoposide in the treatment of hormone-refractory prostate cancer.
- Authors
Hussain, Maha H.; Pienta, Kenneth J.; Redman, Bruce G.; Cummings, Glenn D.; Flaherty, Lawrence E.; Hussain, M H; Pienta, K J; Redman, B G; Cummings, G D; Flaherty, L E
- Abstract
<bold>Background: </bold>Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents.<bold>Methods: </bold>Twenty-two eligible patients with hormone-refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle. Response was evaluated using standard solid tumor response criteria.<bold>Results: </bold>There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overall 1-year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted.<bold>Conclusions: </bold>Single-agent oral etoposide has minimal activity in patients with hormone-refractory prostate cancer.
- Publication
Cancer (0008543X), 1994, Vol 74, Issue 1, p100
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19940701)74:1<100::AID-CNCR2820740118>3.0.CO;2-K